---
schema_version: "secwatch.filing_event.v1"
accession: "0001609550-24-000013"
form_type: "8-K"
ticker: "INSP"
cik: "0001609550"
company_name: "Inspire Medical Systems, Inc."
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:08:42.703598+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Inspire Medical Q4 revenue $192.5M (+40%), first net income quarter $14.8M

## Summary
- Q4 revenue $192.5M (+40% YoY); full year $624.8M (+53%). U.S. revenue $189.4M (+41%).
- Q4 net income $14.8M (diluted EPS $0.49) vs $3.2M ($0.10) a year ago; FY net loss improved 53% to $21.2M.
- Gross margin 85.4% in Q4 vs 83.9% a year ago; FY 2024 guidance 83%-85%.
- Reaffirms FY 2024 revenue guidance of $775M-$785M (24-26% growth).
- Added 78 new U.S. implanting centers in Q4 (total 1,180) and 13 sales territories (total 287).

## SEC filing metadata
- accession: 0001609550-24-000013
- form_type: 8-K
- ticker: INSP
- cik: 0001609550
- company_name: Inspire Medical Systems, Inc.
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609550/000160955024000013/0001609550-24-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609550/000160955024000013/insp-20240206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001609550-24-000013
- JSON: https://secwatch.observer/filing/0001609550-24-000013.json
- Plain text: https://secwatch.observer/filing/0001609550-24-000013.txt

## Key facts
- Earnings Releases
  Inspire Medical Systems, Inc. reported the quarter and year ended December 31, 2023 results: revenue $192.5 million, net income $14.8 million, EPS $0.49. Guidance reaffirmed.
  - Period: the quarter and year ended December 31, 2023
  - Revenue: $192.5 million
  - Net income: $14.8 million
  - EPS: $0.49
  - Guidance: reaffirmed
  - Result: reported results
  source text: sleep apnea, today reported financial results for the quarter and year ended December 31, 2023. Recent Business Highlights and Full Year 2024 Guidance • Generated revenue of $192.5 million in the fourth quarter of 2023, a 40% increase over the same quarter last year, and revenue of $624.8 million in full year 2023, a 53% increase over full year 2022 • Achieved
  evidence_url: https://www.sec.gov/Archives/edgar/data/1609550/000160955024000013/0001609550-24-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.